FDA ad­comm votes unan­i­mous­ly against Pfiz­er's prostate can­cer drug com­bo

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee vot­ed 8-0 against a new in­di­ca­tion for Pfiz­er’s Talzen­na in com­bi­na­tion with Xtan­di for first-line treat­ment of adults with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER